ReACT Phase II trial: a critical evaluation of the use of rindopepimut plus bevacizumab to treat EGFRvIII-positive recurrent glioblastoma
- Type
- Retraction
- Notice date
- 5/1/2016 0:00
- Journal
- Central Nervous System Oncology
- Publisher
- Future Medicine - Future Science Group
- Notice DOI
- 10.2217/cns.16.1
- Original paper DOI
- 10.2217/cns.15.38